RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 1

Registered title, quoted from ClinicalTrials.gov

First in Human Study of SIM0610 in Solid Tumors

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 5 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 5

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  2. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  3. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  4. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
  5. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07348211, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Subjects with locally advanced/metastatic solid tumors confirmed by histology and/or cytology;

    Inclusion criterion 3

    Archived formalin-fixed, paraffin-embedded (FFPE) tumor tissue or fresh biopsy tissue within 5 years must be provided before the first administration

    Inclusion criterion 9

  3. Subjects in Part 1 should have at least one tumor lesion evaluable by RECIST v1.1 criteria, and subjects in Part 2 should have at least one measurable tumor lesion by RECIST v1.1 (lesions that have received radiotherapy or other local treatments cannot be used as target lesions unless there is clear progression of the lesion)

    Inclusion criterion 4

    Symptomatic central nervous system (CNS) metastases occurring within 2 weeks prior to the first dose of study treatment; or requirement for local therapy (e.g., radiotherapy or surgery) for CNS metastases; or requirement for corticosteroid therapy for CNS metastases.

    Exclusion criterion 2

    Failure to recover from adverse events (AEs) induced by prior anti-tumor therapy (i.e., recovery to Grade 1 or baseline level).

    Exclusion criterion 5

    Current participation in a study involving investigational drugs or medical devices, or participation in such a study within 4 weeks prior to the first dose of study treatment.

    Exclusion criterion 6

    Received antibody-drug conjugate (ADC) with topoisomerase I inhibitor (TOP1i) or other ADC targeting EGFR/cMET.

    Exclusion criterion 12

    Received the following medications ≤ 14 days prior to the first dose of study treatment:

    Exclusion criterion 14

    The result of serum pregnancy test within 72 hours prior to the first dose of study treatment is negative;

    Exclusion criterion 23

    They use highly effective contraceptive methods from the time of signing the informed consent form (ICF) until 180 days after the last dose of study treatment.

    Exclusion criterion 24

    Male subjects with female partners of childbearing potential are excluded unless they use highly effective contraceptive methods from the time of signing the ICF until 180 days after the last dose of study treatment.

    Exclusion criterion 25

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

    Inclusion criterion 6

  5. Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).

    Exclusion criterion 18

  6. Pregnant or lactating women. For women of childbearing potential (WOCBP), they are also excluded unless:

    Exclusion criterion 22

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07348211, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily participate and sign the informed consent form
  • At least 18 years old, male or female
  • Subjects with locally advanced/metastatic solid tumors confirmed by histology and/or cytology;
  • Subjects in Part 1 should have at least one tumor lesion evaluable by RECIST v1.1 criteria, and subjects in Part 2 should have at least one measurable tumor lesion by RECIST v1.1 (lesions that have received radiotherapy or other local treatments cannot be used as target lesions unless there is clear progression of the lesion)
  • Subjects with locally advanced/metastatic solid tumors who have failed standard treatment: Part 1: Subjects with solid tumors who have experienced disease progression during/after at least one previous standard systemic anti-tumor regimen and are not suitable for standard treatment. Part 2: Non-small cell lung cancer, liver cancer, head and neck squamous cell carcinoma, colorectal cancer that have experienced disease progression during/after at least one previous standard systemic anti-tumor regimen and are not suitable for standard treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Expected survival period ≥ 12 weeks
  • Adequate organ and bone marrow function
  • Archived formalin-fixed, paraffin-embedded (FFPE) tumor tissue or fresh biopsy tissue within 5 years must be provided before the first administration

Exclusion Criteria:

  • A history of active second primary malignancy within the past 2 years, except for localized tumors that are considered cured and have a low risk of recurrence as assessed by the investigator.
  • Symptomatic central nervous system (CNS) metastases occurring within 2 weeks prior to the first dose of study treatment; or requirement for local therapy (e.g., radiotherapy or surgery) for CNS metastases; or requirement for corticosteroid therapy for CNS metastases.
  • A history of non-infectious interstitial lung disease (ILD)/pulmonary inflammation requiring corticosteroid treatment; current ILD/pulmonary inflammation; or suspected ILD/pulmonary inflammation that cannot be ruled out by screening imaging.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites, or occurrence of such effusions requiring drainage or medical intervention within 4 weeks prior to the first dose of study treatment.
  • Failure to recover from adverse events (AEs) induced by prior anti-tumor therapy (i.e., recovery to Grade 1 or baseline level).
  • Current participation in a study involving investigational drugs or medical devices, or participation in such a study within 4 weeks prior to the first dose of study treatment.
  • Receipt of the following therapies prior to the first dose of study treatment:
  • Cytotoxic therapy within 3 weeks; or anti-tumor targeted small-molecule drugs (e.g., tyrosine kinase inhibitors) within 2 weeks.
  • Anti-tumor antibody-based immune checkpoint inhibitors, antibody-drug conjugates (ADCs), or other anti-tumor biologics within the shorter of 5 half-lives or 4 weeks.
  • Traditional Chinese medicines (TCMs)/herbal preparations with anti-tumor indications within 2 weeks.
  • Radiotherapy within 4 weeks.
  • Received antibody-drug conjugate (ADC) with topoisomerase I inhibitor (TOP1i) or other ADC targeting EGFR/cMET.
  • Received any live vaccine within 4 weeks prior to the first dose of study treatment.
  • Received the following medications ≤ 14 days prior to the first dose of study treatment:
  • Strong or moderate CYP3A4 induction/inhibitor;
  • Drugs known to be at risk for torsade de pointes (TdP);
  • Drugs associated with QTcF interval prolongation (TdP risk equivocal).
  • Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
  • A history of clinically significant cardiovascular diseases within 6 months prior to the first dose of study treatment, including but not limited to myocardial infarction, severe/unstable angina pectoris, primary cardiomyopathy, cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction) or congestive heart failure (New York Heart Association [NYHA] Functional Classification > Class II); symptomatic coronary artery disease requiring pharmacotherapy.
  • A history of allogeneic organ transplantation or graft-versus-host disease (GVHD).
  • A history of hypersensitivity to the active ingredients, inactive excipients of SIM0610, or drugs with similar chemical structures or classifications to SIM0610.
  • Pregnant or lactating women. For women of childbearing potential (WOCBP), they are also excluded unless:
  • The result of serum pregnancy test within 72 hours prior to the first dose of study treatment is negative;
  • They use highly effective contraceptive methods from the time of signing the informed consent form (ICF) until 180 days after the last dose of study treatment.
  • Male subjects with female partners of childbearing potential are excluded unless they use highly effective contraceptive methods from the time of signing the ICF until 180 days after the last dose of study treatment.
  • Any other conditions that may increase subject-related risks or interfere with the interpretation of study results, and that, in the investigator's judgment, render the subject unsuitable for study enrollment.

Quoted from ClinicalTrials.gov, NCT07348211, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07348211, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07348211